Andrei Shustov
Chief Tech/Sci/R&D Officer bij CELLECTAR BIOSCIENCES, INC.
Vermogen: 219 047 $ op 31-03-2024
Profiel
Andrei Shustov is currently a Senior Vice President-Medical at Cellectar Biosciences, Inc. He previously worked as a Senior Medical Director-Late Stage Clinical at Seagen Inc. Shustov earned a doctorate degree from S.
I.
Georgievsky's Medical Academy in 1987.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 08-12-2023 | 55 037 ( 0.45% ) | 219 047 $ | 31-03-2024 |
Actieve functies van Andrei Shustov
| Bedrijven | Functie | Begin |
|---|---|---|
| CELLECTAR BIOSCIENCES, INC. | Chief Tech/Sci/R&D Officer | 15-02-2023 |
Eerdere bekende functies van Andrei Shustov
| Bedrijven | Functie | Einde |
|---|---|---|
| SEAGEN INC. | Corporate Officer/Principal | - |
Opleiding van Andrei Shustov
| S. I. Georgievsky's Medical Academy | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| CELLECTAR BIOSCIENCES, INC. | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
Seagen Inc.
 Seagen Inc. Pharmaceuticals: MajorHealth Technology Seagen Inc. is a biotechnology company, which engages in the development and commercialization of targeted therapies for the treatment of cancer. It also focuses on the advancement of therapies for solid tumors and blood-related cancers. Its products include Adcetris, Padcev, Tivdak, and Tukysa. The company was founded by Clay B. Siegall and H. Perry Fell on July 15, 1997 and is headquartered in Bothell, WA. | Health Technology |
